CRNX
Price
$32.37
Change
+$1.10 (+3.52%)
Updated
Apr 23 closing price
Capitalization
2.91B
14 days until earnings call
XENE
Price
$37.59
Change
+$0.86 (+2.34%)
Updated
Apr 23 closing price
Capitalization
2.81B
19 days until earnings call
Ad is loading...

CRNX vs XENE

Header iconCRNX vs XENE Comparison
Open Charts CRNX vs XENEBanner chart's image
Crinetics Pharmaceuticals
Price$32.37
Change+$1.10 (+3.52%)
Volume$1.55M
Capitalization2.91B
Xenon Pharmaceuticals
Price$37.59
Change+$0.86 (+2.34%)
Volume$701.87K
Capitalization2.81B
CRNX vs XENE Comparison Chart
Loading...
CRNX
Daily Signalchanged days ago
Gain/Loss if bought
Show more...
XENE
Daily Signalchanged days ago
Gain/Loss if bought
Show more...
View a ticker or compare two or three
VS
CRNX vs. XENE commentary
Apr 24, 2025

To compare these two companies we present long-term analysis, their fundamental ratings and make comparative short-term technical analysis which are presented below. The conclusion is CRNX is a Buy and XENE is a StrongBuy.

Ad is loading...
COMPARISON
Comparison
Apr 24, 2025
Stock price -- (CRNX: $32.38 vs. XENE: $37.55)
Brand notoriety: CRNX and XENE are both not notable
Both companies represent the Biotechnology industry
Current volume relative to the 65-day Moving Average: CRNX: 141% vs. XENE: 98%
Market capitalization -- CRNX: $2.91B vs. XENE: $2.81B
CRNX [@Biotechnology] is valued at $2.91B. XENE’s [@Biotechnology] market capitalization is $2.81B. The market cap for tickers in the [@Biotechnology] industry ranges from $266.85B to $0. The average market capitalization across the [@Biotechnology] industry is $2.09B.

Long-Term Analysis

It is best to consider a long-term outlook for a ticker by using Fundamental Analysis (FA) ratings. The rating of 1 to 100, where 1 is best and 100 is worst, is divided into thirds. The first third (a green rating of 1-33) indicates that the ticker is undervalued; the second third (a grey number between 34 and 66) means that the ticker is valued fairly; and the last third (red number of 67 to 100) reflects that the ticker is undervalued. We use an FA Score to show how many ratings show the ticker to be undervalued (green) or overvalued (red).

CRNX’s FA Score shows that 0 FA rating(s) are green whileXENE’s FA Score has 2 green FA rating(s).

  • CRNX’s FA Score: 0 green, 5 red.
  • XENE’s FA Score: 2 green, 3 red.
According to our system of comparison, XENE is a better buy in the long-term than CRNX.

Short-Term Analysis

It is best to consider a short-term outlook for a ticker by using Technical Analysis (TA) indicators. We use Odds of Success as the percentage of outcomes which confirm successful trade signals in the past.

If the Odds of Success (the likelihood of the continuation of a trend) for each indicator are greater than 50%, then the generated signal is confirmed. A green percentage from 90% to 51% indicates that the ticker is in a bullish trend. A red percentage from 90% - 51% indicates that the ticker is in a bearish trend. All grey percentages are below 50% and are considered not to confirm the trend signal.

CRNX’s TA Score shows that 5 TA indicator(s) are bullish while XENE’s TA Score has 6 bullish TA indicator(s).

  • CRNX’s TA Score: 5 bullish, 3 bearish.
  • XENE’s TA Score: 6 bullish, 3 bearish.
According to our system of comparison, XENE is a better buy in the short-term than CRNX.

Price Growth

CRNX (@Biotechnology) experienced а +9.47% price change this week, while XENE (@Biotechnology) price change was +11.16% for the same time period.

The average weekly price growth across all stocks in the @Biotechnology industry was +8.04%. For the same industry, the average monthly price growth was -8.89%, and the average quarterly price growth was -12.57%.

Reported Earning Dates

CRNX is expected to report earnings on Aug 08, 2025.

XENE is expected to report earnings on Aug 07, 2025.

Industries' Descriptions

@Biotechnology (+8.04% weekly)

Biotechnology involves genetic or protein engineering to produce medicines/therapies for treating and preventing ailments. The industry also provides crucial ingredients for diagnostics. This multi-billion-dollar industry is heavily focused on research and development, as companies attempt to continually come up with cutting-edge solutions for health. New discoveries for the treatment of diseases provide opportunities for growth for a company in this industry. Discoveries, however, must pass the regulatory approval from the U.S. Food and Drug Administration (FDA) before they can make it to markets. Amgen Inc., Gilead Sciences, Inc. and Celgene Corporation are examples of companies in this industry.

SUMMARIES
Loading...
FUNDAMENTALS
Fundamentals
CRNX($2.91B) and XENE($2.81B) have the same market capitalization . XENE YTD gains are higher at: -4.209 vs. CRNX (-36.671). XENE has higher annual earnings (EBITDA): -276.74M vs. CRNX (-336.07M). CRNX has more cash in the bank: 1.35B vs. XENE (627M). XENE has less debt than CRNX: XENE (9.02M) vs CRNX (51.7M). CRNX has higher revenues than XENE: CRNX (1.04M) vs XENE (0).
CRNXXENECRNX / XENE
Capitalization2.91B2.81B104%
EBITDA-336.07M-276.74M121%
Gain YTD-36.671-4.209871%
P/E RatioN/AN/A-
Revenue1.04M0-
Total Cash1.35B627M216%
Total Debt51.7M9.02M573%
FUNDAMENTALS RATINGS
CRNX vs XENE: Fundamental Ratings
CRNX
XENE
OUTLOOK RATING
1..100
5418
VALUATION
overvalued / fair valued / undervalued
1..100
89
Overvalued
98
Overvalued
PROFIT vs RISK RATING
1..100
5831
SMR RATING
1..100
7660
PRICE GROWTH RATING
1..100
8356
P/E GROWTH RATING
1..100
1004
SEASONALITY SCORE
1..100
14n/a

Tickeron ratings are formulated such that a rating of 1 designates the most successful stocks in a given industry, while a rating of 100 points to the least successful stocks for that industry.

CRNX's Valuation (89) in the Pharmaceuticals Major industry is in the same range as XENE (98) in the Biotechnology industry. This means that CRNX’s stock grew similarly to XENE’s over the last 12 months.

XENE's Profit vs Risk Rating (31) in the Biotechnology industry is in the same range as CRNX (58) in the Pharmaceuticals Major industry. This means that XENE’s stock grew similarly to CRNX’s over the last 12 months.

XENE's SMR Rating (60) in the Biotechnology industry is in the same range as CRNX (76) in the Pharmaceuticals Major industry. This means that XENE’s stock grew similarly to CRNX’s over the last 12 months.

XENE's Price Growth Rating (56) in the Biotechnology industry is in the same range as CRNX (83) in the Pharmaceuticals Major industry. This means that XENE’s stock grew similarly to CRNX’s over the last 12 months.

XENE's P/E Growth Rating (4) in the Biotechnology industry is significantly better than the same rating for CRNX (100) in the Pharmaceuticals Major industry. This means that XENE’s stock grew significantly faster than CRNX’s over the last 12 months.

TECHNICAL ANALYSIS
Technical Analysis
CRNXXENE
RSI
ODDS (%)
Bullish Trend 1 day ago
80%
Bullish Trend 1 day ago
72%
Stochastic
ODDS (%)
Bearish Trend 1 day ago
88%
Bearish Trend 1 day ago
81%
Momentum
ODDS (%)
Bullish Trend 1 day ago
85%
Bullish Trend 1 day ago
73%
MACD
ODDS (%)
Bullish Trend 1 day ago
81%
Bullish Trend 1 day ago
82%
TrendWeek
ODDS (%)
Bullish Trend 1 day ago
80%
Bullish Trend 1 day ago
75%
TrendMonth
ODDS (%)
Bearish Trend 1 day ago
78%
Bullish Trend 1 day ago
75%
Advances
ODDS (%)
Bullish Trend 1 day ago
77%
Bullish Trend 1 day ago
73%
Declines
ODDS (%)
Bearish Trend 9 days ago
80%
Bearish Trend 21 days ago
74%
BollingerBands
ODDS (%)
Bullish Trend 1 day ago
83%
Bullish Trend 1 day ago
74%
Aroon
ODDS (%)
Bearish Trend 1 day ago
84%
Bearish Trend 1 day ago
80%
View a ticker or compare two or three
Ad is loading...
CRNX
Daily Signalchanged days ago
Gain/Loss if bought
Show more...
XENE
Daily Signalchanged days ago
Gain/Loss if bought
Show more...
Interesting Tickers
1D
1W
1M
1Q
6M
1Y
5Y
1 Day
MFs / NAMEPrice $Chg $Chg %
DIERX40.03N/A
N/A
BNY Mellon International Core Equity I
FLDGX12.59N/A
N/A
Meeder Dynamic Allocation Retail
LMNVX114.12N/A
N/A
ClearBridge Value I
LMCHX30.27N/A
N/A
Lord Abbett Mid Cap Stock R6
FIFAX24.78N/A
N/A
American Funds Income Fund of Amer F3

XENE and

Correlation & Price change

A.I.dvisor indicates that over the last year, XENE has been loosely correlated with IDYA. These tickers have moved in lockstep 53% of the time. This A.I.-generated data suggests there is some statistical probability that if XENE jumps, then IDYA could also see price increases.

1D
1W
1M
1Q
6M
1Y
5Y
Ticker /
NAME
Correlation
To XENE
1D Price
Change %
XENE100%
+2.23%
IDYA - XENE
53%
Loosely correlated
+0.91%
KYMR - XENE
52%
Loosely correlated
+6.56%
CRNX - XENE
51%
Loosely correlated
+3.55%
ATXS - XENE
50%
Loosely correlated
+12.55%
RCKT - XENE
50%
Loosely correlated
+2.44%
More